Clinical Trials Logo

Effects of Immunotherapy clinical trials

View clinical trials related to Effects of Immunotherapy.

Filter by:

NCT ID: NCT05885048 Recruiting - Cancer Clinical Trials

Impact of Gonadotoxic Therapies on Fertility

FertiTOX
Start date: December 1, 2023
Phase:
Study type: Observational [Patient Registry]

The goal of this observational study is to learn how gonadotoxic treatments (chemotherapies, radiotherapies or immunotherapies) affect the fertility status of participants with cancer. The main questions it aims to answer are: - in females, if cancer therapies reduce the Anti-Müllerian hormone (AMH) concentration (ovarian reserve); - in males, if cancer therapies reduce sperm concentration (sperm quality).

NCT ID: NCT05468307 Recruiting - Clinical trials for Treatment Side Effects

Study on TIL Engineered With Membrane-Binding Cytokine for the Treatment of Advanced Gynecologic Tumors

Start date: March 10, 2022
Phase: Early Phase 1
Study type: Interventional

This study is to investigate the safety and efficacy on TIL engineered with membrane-binding cytokine (GC203 TIL) for the treatment of patients with advanced gynecologic tumors. Autologous TILs from tumor resections or biopsies are first gene modified (engineered with membrane-binding cytokine) and than expanded before i.v. infusion into the patient after NMA lymphodepletion treatment with cyclophosphamide.

NCT ID: NCT05420922 Recruiting - Clinical trials for Hepatocellular Carcinoma

Real-world Study of Efficacy and Safety of ICIs and TKIs Therapy for HCC

Start date: November 1, 2021
Phase:
Study type: Observational

China is a high-risk area of Hepatocellular Carcinoma (HCC). Although Chinese population accounts for 18.4% of the global population, the number of new HCC patients accounting for about half of the global, which seriously threatens the lives and health of the people. The investigators establish multi-center, retrospective research methods, collecting the data of HCC treatment with system treatment (ICIs and TKIs) plus or without local treatment in the last 3 years, comprehensive assessment of their efficacy and safety, explore whether the efficacy of system treatment combination local treatment showed better effect compared with system or local monotherapy. Our study will find a new way to improve the prognosis of HCC patients.

NCT ID: NCT05142475 Recruiting - Breast Cancer Clinical Trials

Study on TIL for the Treatment of Advanced Breast Cancer

Start date: November 19, 2021
Phase: Early Phase 1
Study type: Interventional

This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy (GC 101 TIL) in patients with advanced breast cancer. Autologous TILs are expanded from tumor resections or biopsies and infused i.v. into the patient after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.

NCT ID: NCT05098197 Recruiting - Clinical trials for Treatment Side Effects

Study on TIL for the Treatment of Advanced Hepatobiliary-Pancreatic Cancers

Start date: September 26, 2021
Phase: Early Phase 1
Study type: Interventional

This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy in patients with advanced hepatobiliary-pancreatic cancers. Autologous TILs are expanded from tumor resections or biopsies and infused i.v. into the patient after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.

NCT ID: NCT05098184 Recruiting - Advanced Melanoma Clinical Trials

Study on TIL for the Treatment of Advanced Melanoma

Start date: September 26, 2021
Phase: Early Phase 1
Study type: Interventional

This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy in patients with advanced melanoma. Autologous TILs are expanded from tumor resections or biopsies and infused i.v. into the patient after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.

NCT ID: NCT05098171 Recruiting - Clinical trials for Treatment Side Effects

Study on Signal Switch Receptor Modified TIL for the Treatment of Advanced Gynecologic Tumors

Start date: September 26, 2021
Phase: Early Phase 1
Study type: Interventional

This study is to investigate the safety and efficacy of signal switch receptor modified TIL (GC201 TIL) in patients with advanced gynecologic tumors. Autologous TILs from tumor resections or biopsies are first gene modified(TGF-β receptor or PD-1 gene modified TILs which could transfer the suppression signal surrounding the microenvironment of tumor bed into persistent T cell activation signal) and than expanded before i.v. infusion into the patient after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.

NCT ID: NCT05087745 Recruiting - Clinical trials for Advanced Solid Tumor

A Clinical Study on TIL for the Treatment of Advanced Solid Tumors

Start date: December 10, 2021
Phase: Early Phase 1
Study type: Interventional

This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy in patients with advanced solid tumors. Autologous TILs are expanded from tumor resections or biopsies and infused i.v. into the patient after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.

NCT ID: NCT04813380 Completed - Clinical trials for Effects of Immunotherapy

Serum MicroRNAs 223 and 146a in Allergic Rhinitis Patients as Biomarkers for Efficacy of Sublingual Immunotherapy

Start date: July 27, 2021
Phase: Phase 3
Study type: Interventional

The aim of the study is: - to evaluate the serum levels of miR-223 and miRNA146a and to assess their correlation with disease severity in allergic rhinitis patients and their role as biomarkers for efficacy of sublingual immunotherapy. - also to find if high sensitivity CRP can be an easy non-expensive test for diagnosis and follow up of allergic rhinitis patients.

NCT ID: NCT03638375 Active, not recruiting - Adverse Drug Event Clinical Trials

TIL and Anti-PD1 in Metastatic Melanoma

ACTME
Start date: July 31, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

The ACTME study is an investigator initiated, single center phase I/II clinical trial for patients with progressive unresectable stage III or stage IV melanoma. The trial consists of both a phase I part to determine safety and feasibility and a phase II part to evaluate first clinical activity of IFN-alpha, nivolumab and TIL. The treatment with IFN-alpha will be added after the combination of TIL and nivolumab has proven to be safe.